Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Doubtful On Cost-Effectiveness Of Tarceva

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.’s National Institute for Health and Clinical Excellence is asking for a further cost-effectiveness analysis of Roche’s Tarceva to weigh against the cost effectiveness of AstraZeneca’s Iressa.

You may also be interested in...

Limited Returns For Roche And AstraZeneca In Lung Cancer As NICE Restricts Tarceva And Iressa

NICE’s decision to severely restrict second-line use of Roche’s Tarceva and AstraZeneca’s Iressa will not help distance the drugs sufficiently from a chasing pack, including Boehringer’s Giotrif.

NICE Clears Botox For Chronic Migraine, With Therapy “Stopping Rules”

With rules in place about when to stop therapy, the U.K.'s National Institute for Health and Clinical Excellence clears Allergan's botulinum toxin, Botox for use as prophylaxis in patients with chronic migraine and who have tried other therapies.

NICE, In Final Decision, Rejects Roche's Tarceva For Lung Cancer Maintenance

The benefits of Roche's Tarceva as maintenance therapy for lung cancer are uncertain and the drug is not cost-effective, the U.K.'s cost regulator concludes in final guidance.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts